IL149995A0 - Depsipeptides and pharmaceutical compositions containing the same - Google Patents

Depsipeptides and pharmaceutical compositions containing the same

Info

Publication number
IL149995A0
IL149995A0 IL14999500A IL14999500A IL149995A0 IL 149995 A0 IL149995 A0 IL 149995A0 IL 14999500 A IL14999500 A IL 14999500A IL 14999500 A IL14999500 A IL 14999500A IL 149995 A0 IL149995 A0 IL 149995A0
Authority
IL
Israel
Prior art keywords
depsipeptides
same
pharmaceutical compositions
compositions containing
grant
Prior art date
Application number
IL14999500A
Other languages
English (en)
Original Assignee
Xcyte Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26865325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL149995(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xcyte Therapies Inc filed Critical Xcyte Therapies Inc
Publication of IL149995A0 publication Critical patent/IL149995A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14999500A 1999-12-08 2000-12-06 Depsipeptides and pharmaceutical compositions containing the same IL149995A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16973199P 1999-12-08 1999-12-08
US19358200P 2000-03-30 2000-03-30
PCT/US2000/033169 WO2001042282A1 (fr) 1999-12-08 2000-12-06 Depsipeptide et ses congeneres destines a etre utilises en tant qu'immunodepresseurs

Publications (1)

Publication Number Publication Date
IL149995A0 true IL149995A0 (en) 2002-12-01

Family

ID=26865325

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14999500A IL149995A0 (en) 1999-12-08 2000-12-06 Depsipeptides and pharmaceutical compositions containing the same
IL149995A IL149995A (en) 1999-12-08 2002-06-03 Depsipeptides and pharmaceutical compositions containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149995A IL149995A (en) 1999-12-08 2002-06-03 Depsipeptides and pharmaceutical compositions containing the same

Country Status (16)

Country Link
US (2) US6403555B1 (fr)
EP (3) EP1438966B1 (fr)
JP (4) JP4824890B2 (fr)
KR (1) KR20020062956A (fr)
CN (1) CN1414971A (fr)
AT (3) ATE470447T1 (fr)
AU (1) AU762525B2 (fr)
BR (1) BR0016154A (fr)
CA (1) CA2393682C (fr)
DE (3) DE60033453T2 (fr)
DK (1) DK1438966T3 (fr)
ES (3) ES2282751T3 (fr)
HK (2) HK1049849B (fr)
IL (2) IL149995A0 (fr)
PT (1) PT1438966E (fr)
WO (1) WO2001042282A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP1313872A1 (fr) * 2000-09-01 2003-05-28 Fujisawa Pharmaceutical Co., Ltd. Procede de preparation de fr901228
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
US6632553B2 (en) * 2001-03-27 2003-10-14 Mti Microfuel Cells, Inc. Methods and apparatuses for managing effluent products in a fuel cell system
JP4238728B2 (ja) * 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
CA2495354A1 (fr) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. Agent inhibant la degradation de la matrice extracellulaire du cartilage articulaire
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (fr) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
DE602004027244D1 (de) * 2003-06-27 2010-07-01 Astellas Pharma Inc Therapeutisches mittel für ein weichteilsarkom
WO2005007109A2 (fr) * 2003-07-09 2005-01-27 Henry Ford Health System Procedes et compositions destines a la cancerotherapie et mettant en oeuvre un nouvel adenovirus
WO2005030239A2 (fr) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Agent antitumoral
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (fr) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
EP1812036A2 (fr) * 2004-11-17 2007-08-01 The University Of Chicago Inhibiteurs de l'histone desacetylase et leurs methodes d'utilisation
EP1824831A2 (fr) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
CA2615105A1 (fr) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Inhibiteurs de l'histone deacetylase
JP2009507081A (ja) * 2005-09-07 2009-02-19 ブレインセルス，インコーポレイティド ＨＤａｃ阻害による神経発生の調整
CA2630216A1 (fr) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Derives de metabolites de l'inhibiteur de hdac fk228
EP1976835A2 (fr) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Inhibiteurs des histone desacetylases
ES2426445T3 (es) 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
EP2012801A4 (fr) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc Thérapie de combinaison de gemcitabine
WO2007146730A2 (fr) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Thérapie à base d'inhibiteurs de désacétylase (dac)
CA2654566A1 (fr) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Forme posologique solide a administrer par voie orale contenant un activateur
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
CA2670223A1 (fr) * 2006-11-22 2008-05-29 Karus Therapeutics Limited Depsipeptides et leur utilisation therapeutique
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
EP2450049A1 (fr) * 2006-12-29 2012-05-09 Gloucester Pharmaceuticals, Inc. Traitements du cancer a base de romidepsine
CA2674309A1 (fr) 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Preparation de la romidepsine
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
WO2008151306A1 (fr) * 2007-06-05 2008-12-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Synthèse de composés cyclodepsipeptide ayant une activité antinéoplasique et/ou antimicrobienne
GB0715750D0 (en) * 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
CA2709272C (fr) * 2007-12-19 2015-03-10 Abbott Laboratories Reactif d'extraction d'un immunosuppresseur pour dosages immunologiques
US8999383B2 (en) 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
CA2725278A1 (fr) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides et leur utilisation therapeutique
EP2293845A1 (fr) * 2008-05-22 2011-03-16 Karus Therapeutics Limited Depsipeptides et leur utilisation thérapeutique
CA2763299C (fr) * 2009-06-26 2015-11-24 Asan Laboratories Co., Ltd. Methode traitement ou d'amelioration de toxicites mucocutanees ou oculaires
TWI412359B (zh) * 2009-07-07 2013-10-21 Asan Lab Co Ltd 組織蛋白去乙醯酵素抑制劑在製備治療或減緩黏膜／皮膚或眼睛毒性或副作用之藥物的用途
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2012094598A2 (fr) 2011-01-07 2012-07-12 Merrion Research Iii Limited Compositions pharmaceutiques de fer pour administration orale
JP6214397B2 (ja) * 2011-09-30 2017-10-18 国立大学法人東北大学 新規ホスファチジルイノシトール３キナーゼ阻害剤及び医薬組成物
JP6492003B2 (ja) 2012-03-30 2019-03-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CN110760564A (zh) * 2019-10-16 2020-02-07 菲诺克生物科技(上海)有限公司 细胞周期检测方法及其所用试剂与试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268516A (en) 1978-10-11 1981-05-19 Pfizer Inc. [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
AU3972193A (en) 1992-04-07 1993-11-08 Scripps Research Institute, The Method for inducing tolerance to an antigen using butyrate
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5591717A (en) 1994-04-06 1997-01-07 Rojko; Jennifer L. Branched apogenic peptide for inducing apoptosis
WO1995033823A1 (fr) 1994-06-03 1995-12-14 The United States Of America, Represented By The Secretary Of The Navy Procedes de stimulation selective de la proliferation des cellules t
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5962019A (en) 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5891653A (en) 1995-12-29 1999-04-06 Attfield; Derrick Cecil Method of suppressing graft rejection by means of stress proteins
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
EP0972012A4 (fr) 1997-03-03 2004-09-29 Univ Duke Immunodepression
DE19713626A1 (de) * 1997-04-02 1998-10-08 Bayer Ag Neue Thiodepsipeptide zur Bekämpfung von Endoparasiten und ein einfaches Verfahren zu ihrer Herstellung
WO1998046640A2 (fr) 1997-04-15 1998-10-22 Coulter International Corp. Procedes et compositions permettant d'induire l'immunosuppression
EP1010705A4 (fr) 1997-09-02 2004-09-15 Sumitomo Pharma Derives tetrapeptides cycliques et leur utilisation medicinale
AU9395998A (en) 1997-09-17 1999-04-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
AU9398398A (en) 1997-09-22 1999-04-12 Sloan-Kettering Institute For Cancer Research Reverse prenyl compounds as immunosuppressants
WO1999025703A1 (fr) 1997-11-14 1999-05-27 Merck & Co., Inc. Triterpenes tetracycliques immunodepresseurs
AU1864999A (en) 1997-12-15 1999-07-05 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
JPH11180873A (ja) 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
US6001815A (en) * 1997-12-25 1999-12-14 Nisshin Flour Milling Co., Ltd. Depsipeptides containing N-substituted glycine residue
US6211145B1 (en) * 1997-12-25 2001-04-03 Nisshin Flour Milling Co., Ltd. Bicyclic depsipeptides
EP0931792B1 (fr) * 1998-01-27 2004-01-07 Nisshin Seifun Group Inc. Depsipeptides comportant des acides aminés non naturelles
US6287843B1 (en) 1998-04-03 2001-09-11 Pioneer Hi-Bred International, Inc. Maize histone deacetylases and their use
KR100611265B1 (ko) * 1999-01-13 2006-08-10 아스텔라스세이야쿠 가부시키가이샤 신규 뎁시펩티드 화합물

Also Published As

Publication number Publication date
DE60011678D1 (de) 2004-07-22
PT1438966E (pt) 2007-05-31
EP1438966A2 (fr) 2004-07-21
EP1438966B1 (fr) 2007-02-14
ES2282751T3 (es) 2007-10-16
HK1049849A1 (en) 2003-05-30
KR20020062956A (ko) 2002-07-31
EP1779859A3 (fr) 2007-05-16
WO2001042282A9 (fr) 2002-05-30
DE60044542D1 (de) 2010-07-22
JP2013107902A (ja) 2013-06-06
HK1070268A1 (en) 2005-06-17
US20020045575A1 (en) 2002-04-18
AU2068001A (en) 2001-06-18
AU762525B2 (en) 2003-06-26
ATE353663T1 (de) 2007-03-15
JP2003516418A (ja) 2003-05-13
IL149995A (en) 2009-09-01
DE60033453D1 (de) 2007-03-29
JP4824890B2 (ja) 2011-11-30
EP1246839A1 (fr) 2002-10-09
CN1414971A (zh) 2003-04-30
US6403555B1 (en) 2002-06-11
JP2011084585A (ja) 2011-04-28
JP2014205714A (ja) 2014-10-30
EP1779859A2 (fr) 2007-05-02
ES2225282T3 (es) 2005-03-16
ATE269354T1 (de) 2004-07-15
WO2001042282A1 (fr) 2001-06-14
DK1438966T3 (da) 2007-06-11
EP1779859B1 (fr) 2010-06-09
ES2347284T3 (es) 2010-10-27
BR0016154A (pt) 2003-02-25
CA2393682C (fr) 2012-01-31
ATE470447T1 (de) 2010-06-15
EP1246839B1 (fr) 2004-06-16
CA2393682A1 (fr) 2001-06-14
EP1438966A3 (fr) 2004-08-04
US6548479B1 (en) 2003-04-15
HK1049849B (zh) 2004-12-03
DE60011678T2 (de) 2005-07-14
DE60033453T2 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
IL149995A0 (en) Depsipeptides and pharmaceutical compositions containing the same
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
IL245146A0 (en) Phosphatidyl-inositol 3-kinase delta inhibitors
MXPA04004966A (es) Nucleosidos de 3-beta-d-ribofuranoziltiazol(4,5-d(pirimidina y uso de los mismos.
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
HUP9800115A1 (hu) Rifaximin alkalmazása kriptosporidiózis következtében fellépő hasmenés kezelésére használható gyógyszerkészítmények előállítására
WO2004031129A3 (fr) Nouveaux composes destines au traitement des maladies auto-immunes, des maladies immuno-allergiques et des rejets en cas de greffes d'organes ou de tissus
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
DE60231522D1 (de) Behandlung und vorbeugung von insulin-produzierende zelltransplantatabstossung
BG104091A (en) Cd154 blockade therapty in tissue transplantation of pancreatic isles
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
MX217078B (es) Uso de compuestos de aminoadamantano como inmunorreguladores.
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
LT2002105A (en) Novel use of siberian fir oil
MX9801091A (es) Uso combinado de interleukina-10 y ciclosporina para terapia de inmunosupresion.
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture